Cargando…

Targeting efficacy of spironolactone in patients with heart failure with preserved ejection fraction: the TOPCAT study

AIMS: We aimed to explore the heterogeneous treatment effects (HTEs) for spironolactone treatment in patients with Heart failure with preserved ejection fraction (HFpEF) and examine the efficacy and safety of spironolactone medication, ensuring a better individualized therapy. METHODS AND RESULTS: W...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Hui‐min, Zhan, Rong‐jian, Chen, Xuanyu, Lin, Yi‐fen, Zhang, Shao‐zhao, Zheng, Huigan, Wang, Xueqin, Huang, Meng‐ting, Xu, Chao‐guang, Liao, Xin‐xue, Tian, Ting, Zhuang, Xiao‐dong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871668/ https://www.ncbi.nlm.nih.gov/pubmed/36221795 http://dx.doi.org/10.1002/ehf2.14068

Ejemplares similares

Effect of Spironolactone on Atrial Fibrillation in Patients with Heart Failure with Preserved Ejection Fraction: Post-Hoc Analysis of the Randomized, Placebo-Controlled TOPCAT Trial
por: Neefs, Jolien, et al.
Publicado: (2019)

Clinical implication of pulmonary hospitalization in heart failure with preserved ejection fraction: from the TOPCAT
por: Dong, Bin, et al.
Publicado: (2020)

Impact of diabetes on serum biomarkers in heart failure with preserved ejection fraction: insights from the TOPCAT trial
por: De Marco, Corrado, et al.
Publicado: (2021)

Phenotypes of heart failure with preserved ejection fraction and effect of spironolactone treatment
por: Choy, Manting, et al.
Publicado: (2022)

Leucocyte count predicts cardiovascular risk in heart failure with preserved ejection fraction: insights from TOPCAT Americas
por: Bajaj, Navkaranbir S., et al.
Publicado: (2020)

Associations of Left Ventricular Structure and Function With Blood Pressure in Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial
por: Wei, Fang‐Fei, et al.
Publicado: (2020)

Influence of polypharmacy on patients with heart failure with preserved ejection fraction: a retrospective analysis on adverse outcomes in the TOPCAT trial
por: Wu, Yuzhong, et al.
Publicado: (2020)

Impact of Sex on Ventricular‐Vascular Stiffness and Long‐Term Outcomes in Heart Failure With Preserved Ejection Fraction: TOPCAT Trial Substudy
por: Beale, Anna L., et al.
Publicado: (2019)

Association of liver fibrosis risk scores with clinical outcomes in patients with heart failure with preserved ejection fraction: findings from TOPCAT
por: Peters, Anthony E., et al.
Publicado: (2021)

Spironolactone Use and Improved Outcomes in Patients With Heart Failure With Preserved Ejection Fraction With Resistant Hypertension
por: Tsujimoto, Tetsuro, et al.
Publicado: (2020)

A composite metric for predicting benefit from spironolactone in heart failure with preserved ejection fraction
por: Belkin, Mark N., et al.
Publicado: (2021)

C(2)HEST score predicts clinical outcomes in heart failure with preserved ejection fraction: a secondary analysis of the TOPCAT trial
por: Liang, Weihao, et al.
Publicado: (2021)

Sex Differences in Characteristics and Outcomes in Elderly Heart Failure Patients With Preserved Ejection Fraction: A Post-hoc Analysis From TOPCAT
por: Sun, Jiaxing, et al.
Publicado: (2021)

Comparative Outcomes of a Transthyretin Amyloid Cardiomyopathy Cohort Versus Patients With Heart Failure With Preserved Ejection Fraction Enrolled in the TOPCAT Trial
por: Kim, Morris M., et al.
Publicado: (2023)

Weight cycling and risk of clinical adverse events in patients with heart failure with preserved ejection fraction: a post-hoc analysis of TOPCAT
por: Tan, Yi, et al.
Publicado: (2023)

Efficacy and safety of spironolactone in the heart failure with mid-range ejection fraction and heart failure with preserved ejection fraction: A meta-analysis of randomized clinical trials
por: Xiang, Yajie, et al.
Publicado: (2019)

Effects of spironolactone in heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials
por: Li, Shuai, et al.
Publicado: (2018)

Body Mass Index, Natriuretic Peptides, and Risk of Adverse Outcomes in Patients With Heart Failure and Preserved Ejection Fraction: Analysis From the TOPCAT Trial
por: Pandey, Ambarish, et al.
Publicado: (2018)

Prognostic Implication of Liver Function Tests in Heart Failure With Preserved Ejection Fraction Without Chronic Hepatic Diseases: Insight From TOPCAT Trial
por: Liang, Weihao, et al.
Publicado: (2021)

TOPCAT misses its primary endpoint: Should spironolactone be abandoned in HFpEF?
por: ElGuindy, Ahmed M.
Publicado: (2013)

Association of β-Blocker Use With Heart Failure Hospitalizations and Cardiovascular Disease Mortality Among Patients With Heart Failure With a Preserved Ejection Fraction: A Secondary Analysis of the TOPCAT Trial
por: Silverman, Daniel N., et al.
Publicado: (2019)

Spironolactone use is associated with improved outcomes in heart failure with mid‐range ejection fraction
por: Enzan, Nobuyuki, et al.
Publicado: (2020)

Association between dosing of spironolactone and outcomes in heart failure with preserved ejection fraction patients combined with chronic kidney disease------Balance of efficacy and risk
por: Li, Jun-Feng, et al.
Publicado: (2023)

Heart failure with preserved ejection fraction
por: Rigolli, Marzia, et al.
Publicado: (2013)

Heart failure with preserved ejection fraction
por: ElGuindy, Ahmed, et al.
Publicado: (2012)

Personalized Management for Heart Failure with Preserved Ejection Fraction
por: Lin, Chang-Yi, et al.
Publicado: (2023)

Distinct implications of body mass index in different subgroups of nonobese patients with heart failure with preserved ejection fraction: a latent class analysis of data from the TOPCAT trial
por: Dong, Bin, et al.
Publicado: (2022)

Rationale and Study Design of the Withdrawal of Spironolactone for Heart Failure with Improved Left Ventricular Ejection Fraction
por: Hyun, Junho, et al.
Publicado: (2021)

Atrial Fibrillation can adversely impact Heart Failure with Preserved Ejection Fraction by its association with Heart Failure Progression and Mortality: A Post-Hoc Propensity Score–Matched Analysis of the TOPCAT Americas Trial
por: Saksena, Sanjeev, et al.
Publicado: (2023)

Biomarkers in heart failure with preserved ejection fraction
por: Meijers, W. C., et al.
Publicado: (2016)

Management of heart failure with preserved ejection fraction
por: Gard, Emma, et al.
Publicado: (2020)

Managing heart failure with preserved ejection fraction
por: Davidson, Alexander, et al.
Publicado: (2020)

Biomarkers in Heart Failure with Preserved Ejection Fraction
por: Bayes-Genis, Antoni, et al.
Publicado: (2022)

Comorbidities in heart failure with preserved ejection fraction
por: Deichl, Andrea, et al.
Publicado: (2022)

Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
por: Kanagala, Prathap, et al.
Publicado: (2019)

Poorer Exercise Accommodation of Regional Systolic Myocardial Motion after Spironolactone Treatment in Heart Failure Patients with Preserved Ejection Fraction and Ventricular Dyssynchrony
por: Yu, Chih-Chieh, et al.
Publicado: (2021)

Plasma Biomarker Profiling in Heart Failure Patients with Preserved Ejection Fraction before and after Spironolactone Treatment: Results from the Aldo-DHF Trial
por: Schnelle, Moritz, et al.
Publicado: (2021)

Effect of AZD9977 and spironolactone on serum potassium in heart failure with preserved or mildly reduced ejection fraction, and renal impairment: A randomized trial
por: Squire, Iain B., et al.
Publicado: (2022)

Treatment response to spironolactone in patients with heart failure with preserved ejection fraction: a machine learning-based analysis of two randomized controlled trials
por: Kresoja, Karl-Patrik, et al.
Publicado: (2023)

Prognostic Value of Anxiety Between Heart Failure With Reduced Ejection Fraction and Heart Failure With Preserved Ejection Fraction
por: Lin, Tin‐Kwang, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_qr75uvkj4mi6n73d8svcvjtie7